Sharon M. Moe, MD
Stuart A. Kleit Professor of Nephrology
950 W. Walnut Street R2-202
Indianapolis, IN 46202
Titles & Appointments
- Professor of Medicine
- Adjunct Professor of Anatomy & Cell Biology
- Division Director
- Adjunct Professor for Anatomy and Cell Biology
- Nephrology Section Chief, Eskenazi Health
My research investigates the relationship of kidney disease, vascular calcification, bone, and disorders of mineral metabolism known as CKD-Mineral Bone Disorder (CKD-MBD). Our research is funded by the NIH, Veterans Administration, Food and Drug Administration, and industry and utilizes in vivo, ex vivo and in vitro techniques to investigate the pathophysiology of arterial medial calcification and bone disease. We are using a naturally occurring rat model of CKD that spontaneously develops all manifestations of CKD-MBD to study 1) mechanisms by which matrix vesicles propagate arterial calcification, 2) how oxidative stress alters vasculature, 3) the role of advanced glycation end product cross linking of bone collagen predisposes to fracture, 4) mechanisms of sudden cardiac death, 5) how impaired muscle function occurs with progressive CKD, and 6) micro RNA as biomarkers. We also have active investigator initiated clinical trials studying the natural progression of frailty and muscle weakness in patients as they start on dialysis, novel phosphate binders and the effect on phosphate balance, how nutrition can be enhanced in patients on dialysis, and the use of pioglitazone as a treatment for ADPKD.
Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters.
Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials.
Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
Intracellular calcium increases in vascular smooth muscle cells with progression of chronic kidney disease in a rat model.
Reduced skeletal muscle function is associated with decreased fiber cross-sectional area in the Cy/+ rat model of progressive kidney disease.
The effect of a diet containing 70% protein from plants on mineral metabolism and musculoskeletal health in chronic kidney disease.
The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
Subcutaneous nerve activity and mechanisms of sudden death in a rat model of chronic kidney disease.
Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial.
Cortical bone mechanical properties are altered in an animal model of progressive chronic kidney disease.
Nicotinamide treatment in a murine model of familial tumoral calcinosis reduces serum Fgf23 and raises heart calcium.
Changes in skeletal collagen cross-links and matrix hydration in high- and low-turnover chronic kidney disease.
A comparison of calcium to zoledronic acid for improvement of cortical bone in an animal model of CKD.
Adverse mandibular bone effects associated with kidney disease are only partially corrected with bisphosphonate and/or calcium treatment.
What have we learned about chronic kidney disease-mineral bone disorder from the EVOLVE and PRIMO trials?
Decreased microRNA is involved in the vascular remodeling abnormalities in chronic kidney disease (CKD).
Worsening endothelial function with efavirenz compared to protease inhibitors: a 12-month prospective study.
Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease.
The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat.
Activation of arterial matrix metalloproteinases leads to vascular calcification in chronic kidney disease.
Optimal vitamin D, calcitriol, and vitamin D analog replacement in chronic kidney disease: to D or not to D: that is the question.
RhoA/Rho kinase (ROCK) alters fetuin-A uptake and regulates calcification in bovine vascular smooth muscle cells (BVSMC).
A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease.
Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease.
Hepatitis C increases the risk of progression of chronic kidney disease in patients with glomerulonephritis.
R-568 reduces ectopic calcification in a rat model of chronic kidney disease-mineral bone disorder (CKD-MBD).
Verapamil inhibits calcification and matrix vesicle activity of bovine vascular smooth muscle cells.
Oral fish oil supplementation raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients--a pilot study.
High glucose increases the expression of Cbfa1 and BMP-2 and enhances the calcification of vascular smooth muscle cells.
Fetuin-A uptake in bovine vascular smooth muscle cells is calcium dependent and mediated by annexins.
The mechanisms of uremic serum-induced expression of bone matrix proteins in bovine vascular smooth muscle cells.
Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States.
Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD).
American Medical Association
American Society for Clinical Investigation
American Board of Internal Medicine - Nephrology